Tetrabenazine in Huntington's Disease Chorea
Author(s) -
Shilpa Chitnis,
Cherian Abraham Karunapuzha
Publication year - 2009
Publication title -
clinical medicine therapeutics
Language(s) - English
Resource type - Journals
ISSN - 1179-1713
DOI - 10.4137/cmt.s2134
Subject(s) - chorea , tetrabenazine , medicine , huntington's disease , movement disorders , choreiform movement , dystonia , botulinum toxin , disease , psychiatry , dopamine , neuroscience , anesthesia , psychology , dyskinesia , parkinson's disease
Huntington's disease (HD) is a heredodegenerative neurological disorder with chorea and other hyperkinetic movement disorders being part of the disease spectrum. These along with cognitive and neurobehavioral manifestations contribute significantly to patient's disability. Several classes of drugs have been used to treat the various symptoms of HD. These include typical and atypical neuroleptics along with dopamine depletors for treatment of chorea and antidepressants, GABA agonists, antiepileptic medications, cholinesterase inhibitors, antiglutamatergic drugs and botulinum toxin for treatment of other manifestations. Tetrabenazine (TBZ), a dopamine depleting medication was recently approved by the US FDA for treatment of chorea in HD. The purpose of this article is to briefly review information regarding HD and current treatments for chorea and specifically focus on TBZ and review the literature related to its use in HD chorea.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom